The present data of our preclinical study indicates that
prolonged Ropren1 treatment on anxiety-related behavior after
impairment induced by a single injection of Ab 25-35 peptide can
be explained by its direct and/or indirect dual action on emotional
functions of the brain and modifications of monoamines and its
metabolites levels. Taken together, it can be proposed that the
positive effect of prolonged Ropren1 treatment on anxiety-related
brain function after impairment induced by a single injection of Ab
25-35 peptide into the brain is connected with its mutual and
complex action on the monoaminergic systems, mainly, dopaminergic
and serotonergic, and/or on oxidative stress. Furthermore,
this is the
first study to show a beneficial effect of prolonged
Ropren1 administration on anxiety-related states induced by Ab
25-35 intracerebroventricular injection in male rats with low
androgen levels. This work promotes more effective creating of the
novel therapeutic targets and strategies for AD treatment.